Toronto, Ontario–(Newsfile Corp. – November 18, 2024) – Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) (“Braxia”, or the “Company”) announced that Jerry Habuda has resigned as a director effective November 12, 2024. Peter Rizakos was appointed on the same date by the remaining directors. Roger McIntyre resigned as a director and CEO effective November 13, 2024. The current directors of the Company are Ahmed Shehata and Peter Rizakos.
About Braxia Scientific Corp.
Braxia Scientific is a medical research and telemedicine company with a clinic that provide innovative ketamine treatments for persons with depression and related disorders. Braxia Health (formerly the Canadian Rapid Treatment Center of Excellence Inc.), operates a multidisciplinary community-based clinic offering rapid-acting treatments for depression located in Mississauga.
FOR FURTHER INFORMATION PLEASE CONTACT:
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.